Chaperone therapy for lysosomal and non-lysosomal protein misfolding diseases-Reference-Cited by-同舟云学术

Chaperone therapy for lysosomal and non-lysosomal protein misfolding diseases

Published:2023-05 Issue:5 Volume:45 Page:251-259
ISSN:0387-7604
Container-title:Brain and Development
language:en
Short-container-title:Brain and Development

Author:

Suzuki Yoshiyuki^ORCID

Funder

Japan Science and Technology Agency

Ministry of Health, Labour and Welfare

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Elsevier BV

Subject

Neurology (clinical),Developmental Neuroscience,General Medicine,Pediatrics, Perinatology and Child Health

Reference35 articles.

1. Chaperone therapy for molecular pathology in lysosomal diseases;Suzuki;Brain Dev,2021

2. Inborn lysosomal diseases;Hers;Gastroenterology,1965

3. Enzyme replacement therapy: conception, chaos and culmination;Brady;Philos Trans R Soc Lond B Biol Sci,2003

4. β-Galactosidase deficiency: an approach to chaperone therapy;Suzuki;J Inherit Metab Dis,2006

5. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities;Suzuki;Perspect Med Chem,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extending diagnostic practices in gyrate atrophy: Enzymatic characterization and the development of an in vitro pyridoxine responsiveness assay;Molecular Genetics and Metabolism;2024-09

2. sp2-Iminosugar azobenzene O-glycosides: Light-sensitive glycosidase inhibitors with unprecedented tunability and switching factors;Bioorganic Chemistry;2024-09

3. The solvatochromic effect of functionalized 6-aminoracil derivatives in light of DFT: FT-IR, TD-DFT, NBO, and FMO studies;Optik;2024-05

4. N‐Methyl‐N‐Alkylaminocyclopentanes: Powerful and Selective β‐d‐Glucocerebrosidase Inhibitors;Helvetica Chimica Acta;2024-02-29